Table 3.
Characteristics of studies analyzed the association of SUVmax with KRAS and Ki-67 in colorectal cancer.
| Authors | Year | Country | Age | No. Patient | Design | Tumor type | Treatment |
|---|---|---|---|---|---|---|---|
| KRAS mutation | |||||||
| Kawada et al. (25) | 2012 | Japan | 68 | 51 | R | CRC | No |
| Chen et al. (26) | 2014 | China | 59 | 121 | R | CRC | Yes |
| Krikelis et al. (16) | 2014 | Greece | 60 | 44 | R | CRC | No |
| Kawada et al. (27) | 2015 | Japan | 65 | 55 | R | CRC | No |
| Lee et al. (29) | 2016 | Korea | 60 | 179 | R | CRC | No |
| Lovinfosse et al. (17) | 2016 | Belgium | 66 | 151 | R | CRC | No |
| Lovinfosse et al. (17) | 2016 | Belgium | 66 | 151 | R | CRC | No |
| Cho et al. (30) | 2017 | Korea | 60 | 184 | R | CRC | NA |
| Oner et al. (33) | 2017 | Turkey | 55 | 55 | R | CRC | No |
| Liu et al. (36) | 2018 | China | 61 | 45 | R | CRC | No |
| Chen et al. (28) | 2019 | China | 58 | 74 | R | CRC | No |
| Guo et al. (31, 37) | 2019 | China | 62 | 132 | R | CRC | No |
| Taguchi et al. (34) | 2019 | Japan | 67 | 40 | R | CRC | No |
| Mao et al. (32) | 2019 | China | 61 | 87 | R | CRC | No |
| Lv et al. (14) | 2019 | China | 56 | 164 | R | CRC | No |
| Arsla et al. (15) | 2020 | Turkey | 65 | 83 | R | CRC | No |
| Wang et al. (35) | 2020 | China | 66 | 76 | R | CRC | No |
| Ki-67 index | |||||||
| Fukuda et al. (18) | 2019 | Japan | 68 | 18 | P | CRC | NO |
| Nakajo et al. (19) | 2014 | Japan | 64 | 30 | P | CRC | YES |
| Song1 (38) | 2019 | China | 59 | 358 | R | Colon | NO |
| Song 2 (38) | 2019 | China | 59 | 358 | R | Rectal | NO |
NA, not available; P, prospective; R, retrospective.